Rapid Micro Biosystems, BARDA sign vaccines sterility testing development contract
As per the terms of the agreement, Rapid Micro Biosystems is expected to receive $2.2m in the first contract year and up to an additional $4.5m in two
The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) from Pfizer and Valneva for their Lyme disease vaccine candidate, PF-07307405.
As per the terms of the agreement, Sanofi-aventis will have access to Belfer’s cancer target identification and validation platform, and translational medicine capabilities. Belfer has licensed Sanofi-aventis an